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Summary 38 
 39 
The American College of Cardiology and the American Heart Association (ACC/AHA) 2017 40 
guidelines for hypertension management lowered blood pressure (BP) thresholds to 130/80 41 
mmHg to define hypertension while the European Society of Cardiology and the European 42 
Society of Hypertension (ESC/ESH) 2018 guidelines retained 140/90 mmHg. Both guidelines 43 
recommend adapting management for older patients with complex health conditions, without 44 
however clear indications on how to adapt. Our aims were to assess the impact of lowering 45 
BP thresholds on the prevalence of elevated BP and BP control, as well as the proportion of 46 
participants with a complex health condition across these BP categories. We used data from 47 
3210 participants in the Lausanne cohort Lc65+ aged between 67 and 80 years. Hypertension 48 
diagnosis and antihypertensive medication use were self-reported. BP was measured three 49 
times at one visit. Some 51% of participants reported having hypertension and 44% reported 50 
taking antihypertensive medication. Compared with ESC/ESH thresholds, the prevalence of 51 
measured elevated BP was 24% percentage points higher and BP control was 24% percentage 52 
points lower using ACC/AHA thresholds. About one out of two participants with elevated BP 53 
and four out of five participants with uncontrolled BP had a complex health condition, i.e. 54 
frailty, multimorbidity or polypharmacy. To comply with ACC/AHA guidelines, considerable 55 
effort would be required to reach BP control. This is a serious challenge because a large share 56 
of hypertensive older adults have complex health conditions, a type of patients for whom 57 
there is no strong evidence on how to manage hypertension. 58 
59 
 
 
 
 
Summary table 60 
What is known about the topic 61 
• The American College of Cardiology and the American Heart Association (ACC/AHA) 62 
2017 guidelines for hypertension management lowered blood pressure (BP) thresholds to 63 
130/80 mmHg to define hypertension 64 
• The European Society of Cardiology and the European Society of Hypertension 65 
(ESC/ESH) 2018 guidelines retained 140/90 mmHg 66 
• Guidelines advise to adapt hypertension management for older patients with complex 67 
health conditions  68 
What this study adds 69 
• Among older adults (67 to 80 years), compared with ESC/ESH thresholds, the prevalence 70 
of elevated BP was 24% percentage points higher (39 vs 63%) and BP control was 24% 71 
percentage points lower (56 vs 32%) using ACC/AHA guidelines.  72 
• About one out of two participants with elevated BP and four out of five participants with 73 
uncontrolled BP had a complex health condition. 74 
• To comply with ACC/AHA guidelines, considerable effort would be required to reach BP 75 
control, a serious challenge especially with the frequent occurrence of complex health 76 
conditions among hypertensive older adults. 77 
78 
 
 
 
 
Introduction  79 
 80 
Recent American and European hypertension management guidelines have proposed different 81 
blood pressure (BP) thresholds to define hypertension as well as different targets for BP 82 
control. In 2017, the American College of Cardiology and the American Heart Association 83 
(ACC/AHA) guidelines lowered the BP thresholds from 140/90 mmHg to 130/80 mmHg [1] 84 
(Table 1). The European Society of Cardiology and the European Society of Hypertension 85 
(ESC/ESH) guidelines 2018 retained the previous thresholds of 140/90 mmHg to define 86 
hypertension [2]. While the absolute health risk associated with a given level of BP increases 87 
substantially with age [3, 4], neither of these guidelines proposed specific thresholds for older 88 
adults.   89 
 90 
Several studies have quantified the impact of lowering BP thresholds to 130/80 mmHg for the 91 
definition of hypertension in the general population, but only few had a specific focus on 92 
older adults [5, 6]. Nonetheless, the impact of lowering BP thresholds may be of major 93 
concern in older adults for several reasons. First, the prevalence of hypertension increases 94 
with age and is already high among older adults, reaching up to 75% in individuals aged 75 95 
years and more [3]. Additionally, BP control rates are not satisfactory with current BP 96 
thresholds [3], hence, with the ACC/AHA threshold at <130/80 mmHg, BP control would be 97 
even more difficult to reach [7]. Second, there is still a strong debate around hypertension 98 
management in older adults, and the benefit-harm balance of targeting a BP below the 99 
ACC/AHA thresholds remains uncertain.   100 
 101 
Compared to middle-aged adults, older adults are at higher risk for cardiovascular disease 102 
(CVD) and a given BP reduction has a larger effect on CVD absolute risk reduction [8]. The 103 
 
 
 
 
recent SPRINT trial confirmed the benefit of targeting a relatively low BP among older adults 104 
[9]. However, whether the results of the SPRINT trial can be applied to the general population 105 
of older patients has been highly debated [10], especially for older adults with complex health 106 
conditions, such as frailty, multimorbidity and polypharmacy. These uncertainties are mainly 107 
due to several studies, which have shown an increased risk of hypotensive-related falls, and 108 
cognitive and physical decline in the oldest-old and frail older adults with low BP [11-13]. As 109 
a result, general warnings to adapt management were included for older patients with complex 110 
health conditions in both guidelines. 111 
 112 
Using data from a large population-based study of older adults [14], we assessed 1) the impact 113 
of lowering BP thresholds on the prevalence of elevated BP and on BP control, and 2) the 114 
proportion of complex health conditions among those with elevated and uncontrolled BP.  115 
 116 
Methods 117 
 118 
Population and data collection 119 
 120 
We used data collected between 2014 and 2016 from participants in the Lausanne cohort 121 
Lc65+ who had complete data on systolic and diastolic BP [14]. The Lausanne cohort Lc65+ 122 
is an ongoing population-based observational study investigating the health in individuals 123 
aged 65 years and more. The cohort consists of three samples recruited upon written consent 124 
at 5 year intervals (2004, 2009, and 2014). For the recruitment of each sample, the Population 125 
Office of the city of Lausanne [15] was requested to extract a list of all residents born in a 126 
specific 5 year range (2004: sample 1, birth year 1934-1938; 2009: sample 2, birth year 1939-127 
1943; 2014: sample 3, 1944-1948). The Population Office of the city of Lausanne is part of 128 
 
 
 
 
the civil registration system of Switzerland; residents have to register moves to and moves 129 
away from Lausanne, as well as any changes in address.  130 
 131 
A random selection of about two thirds of the extracted and eligible population was invited by 132 
mail to participate in the study [16]. Exclusion criteria were residency in a nursing home and 133 
inability to answer questionnaires due to advanced dementia. The study protocol of the cohort 134 
was approved by the Ethics Committee of the Faculty of Biology and Medicine of the 135 
University of Lausanne in Switzerland [14]. For this analysis, we used data collected at the 136 
most recent data collection for each of the three samples, that is, in 2014, 2016 and 2015 for 137 
sample 1, sample 2, and sample 3, respectively. The specific time points for data collection 138 
for each variable are summarized elsewhere [17].  139 
 140 
Data on hypertension diagnosis and antihypertensive medication use were self-reported. BP 141 
was measured at the study center by research assistants using a standardized protocol. BP was 142 
measured after 10 to 20 minutes rest three times during one visit at 5 to 10 minute intervals 143 
using a clinically validated oscillometric automated device (Omron® 907 (HEM-907-E) 144 
digital automatic blood pressure monitor)) [18, 19]. An auscultatory method with an 145 
Erkameter 3000® mercury tensiometer and a Duophon® or a Littmann® stethoscope was 146 
used if the participants had heart rhythm abnormalities. BP measurements were made with 147 
cuffs for various mid-arm circumferences (17-22cm, 22-32 cm and 32-42 cm) on the left arm, 148 
unless for some medical reasons they had to be done on the right. During BP measurements, 149 
participants were asked to relax and sit in a comfortable position, with their back supported, 150 
left arm resting at the level of the heart on a support, and the palm of the hand up. 151 
 152 
Definition of hypertension, antihypertensive medication use, elevated BP and BP control 153 
 
 
 
 
Hypertension was defined as self-reported diagnosis of hypertension by a physician (reported 154 
at baseline or at most recent data collection) or current antihypertensive medication use at 155 
least once a week. Hypertension treatment was defined as self-reported current 156 
antihypertensive medication use at least once a week. 157 
To define elevated BP and BP control, we referred to the definition of hypertension and BP 158 
target recommendations by the ESC/ESH 2018 and the ACC/AHA 2017 guidelines (Table 1). 159 
The European guidelines define hypertension as BP of 140/90 mmHg or higher and the 160 
ACC/AHA guidelines 2017 define hypertension as BP of 130/80 mmHg or higher; we 161 
therefore defined elevated BP-ESC/ESH as BP ≥ 140/90 mmHg and elevated BP-ACC/AHA 162 
as BP ≥ 130/80 mmHg [1, 2].  163 
Regarding BP control, the ESC/ESH guidelines 2018 recommend targeting 130-139/70-79 164 
mmHg in individuals aged 65 years and over and they recommend not to lower BP below 165 
130/80 mmHg. They recommend accounting for the patient’s clinical condition, concomitant 166 
treatments, and frailty status in deciding the BP level to target. They also recommend close 167 
monitoring of adverse effects during treatment. The ACC/AHA guidelines 2017 recommend 168 
targeting < 130/80 mmHg with no consideration of age. In persons aged 65 years and over 169 
with high comorbidity burden and limited life expectancy, they recommend to assess benefits 170 
and risks of treatment intensity. For our analyses, we defined BP control under the ESC/ESH 171 
guidelines among treated patients as BP <140/90 mmHg and BP control under the ACC/AHA 172 
guidelines as BP <130/80 mmHg. 173 
Definition of complex health conditions: frailty, multimorbidity and polypharmacy 174 
Frailty status was determined based on Fried’s phenotype model, which was described 175 
elsewhere [17]. Briefly, the model used a combination of 5 criteria: self-reported shrinking, 176 
 
 
 
 
exhaustion, and low activity and measured weakness, and slowness. Participants were frail if 177 
they had at least three of these five criteria [14, 20]. Multimorbidity was defined when a 178 
participant reported 2 or more chronic diseases [21]. Chronic diseases included self-reported 179 
diagnoses of arthrosis, Alzheimer’s disease, asthma, cancer, heart failure, coronary heart 180 
disease, chronic pulmonary disease, Parkinson’s disease, ulcer, HIV, osteoporosis, 181 
hypercholesterolemia, hypertension and diabetes. Polypharmacy was determined if 182 
participants reported that they were taking five categories of medications at least once a week 183 
[22].  184 
Definition of variables for baseline characteristics 185 
Date of birth and sex were derived from the Population Office file. Socioeconomic 186 
characteristics, and other CVD risk factors, were based on self-report. Financial difficulties 187 
were determined when participants reported that they had had financial difficulties in the past 188 
12 months, or had trouble making ends meet, or received means-tested subsidies for health 189 
insurance or received complementary financial support to supplement old-age pension. 190 
Hypercholesterolemia was determined if participants reported physician-diagnosed high 191 
cholesterol or cholesterol-lowering medication use. Diabetes was determined if participants 192 
reported physician-diagnosed diabetes or medication use for diabetes. History of CVD was 193 
determined if participants reported that they had been diagnosed with: coronary heart disease, 194 
stroke, heart insufficiency, cardiomyopathy, heart valve disease, or other cardiopathy, or if 195 
they reported medication use for the heart. BMI was calculated using measured height and 196 
weight. 197 
 198 
Statistical analyses 199 
 200 
 
 
 
 
We used data from all Lc65+ participants who were still alive and participating at the most 201 
recent data collection and we restricted our analytical sample to participants who had 202 
complete data for BP measures. We estimated the prevalence and 95% confidence interval 203 
(CI) for hypertension, antihypertensive medication use, elevated BP-ESC/ESH and elevated 204 
BP-ACC/AHA stratified by sex and age. Further, among treated hypertensive patients, we 205 
estimated the proportion and 95% CI of individuals with uncontrolled BP stratified by sex and 206 
age. Finally, among participants with elevated BP and with uncontrolled BP according to both 207 
guidelines separately, we estimated the proportion and 95% CI of individuals with a complex 208 
health condition, i.e. with frailty, multimorbidity, polypharmacy and with any one of the 209 
three. 210 
 211 
Results 212 
 213 
Of the 9887 persons invited to participate to the Lc65+ study, 3504 did not respond, 1201 214 
refused to participate, and 451 were removed from the database (death, move outside the 215 
study area, institutionalization, end of life hospitalization, advanced dementia reported by 216 
relatives at enrollment); 4731 (48%) were eventually recruited. At the most recent data 217 
collection with physical measurements, 3651 individuals were still alive and participating. Of 218 
these, 441 had missing data for BP and were excluded from the current analyses, leaving an 219 
analytical sample of 3210 participants (Figure 1). In supplementary analyses, we identified 220 
no major difference between characteristics of the original sample of 3651 individuals and the 221 
analytical sample (supplementary Table S1). 222 
 223 
The analytical sample consisted of 3210 participants aged between 67 and 80 years. The mean 224 
age of participants was 73.3 years (standard deviation (SD): 4.1) and 59% were women 225 
 
 
 
 
(Table 2). In the whole sample, 51% of participants reported having hypertension and 44% 226 
reported taking antihypertensive medication. 35% had hypercholesterolemia, 11% diabetes, 227 
26% a history of CVD and 16% were current smokers. 48% had two or more chronic 228 
diseases, 21% were taking 5 or more medications on a regular basis, and 3.6% were frail. 229 
 230 
The prevalence of elevated BP-ESC/ESH (≥140/90 mmHg) was 39% (95% CI: 37% to 41%) 231 
while the prevalence of elevated BP-ACC/AHA (≥130/80 mmHg) was 63% (95% CI: 61% to 232 
64%) (Table 3), 24% (95% CI: 21% to 26%) percentage points higher. Women had a lower 233 
prevalence of elevated BP compared to men. In terms of absolute difference in the prevalence 234 
of elevated BP when comparing the ACC/AHA thresholds with the ESC/ESH thresholds, 235 
there were no substantial differences across age or sex strata. In supplementary analyses, we 236 
identified no major difference between characteristics of individuals with elevated BP under 237 
the ACC/AHA 2017 guidelines together with normal BP under the ESC/ESH 2018 and the 238 
analytical sample (supplementary Table S1). 239 
 240 
Among participants treated for hypertension, the proportion of controlled BP-ESC/ESH 241 
(<140/90 mmHg) was 56% (95% CI: 54% to 59%) and the proportion of controlled BP-242 
ACC/AHA (<130/80 mmHg) was 32% (95% CI: 30% to 35%), 24% (95% CI: 21% to 28%) 243 
percentage points lower. Women had a higher proportion of controlled BP compared to men 244 
(Figure 2). In terms of absolute difference in the proportion of BP control when comparing 245 
ACC/AHA threshold and ESC/ESH threshold, there were no substantial differences across 246 
age and sex strata. 247 
 248 
Among participants with elevated BP-ESC/ESH, 2.6% (95% CI: 1.8% to 3.6%) were frail, 249 
49% (95% CI: 46% to 51%) were multimorbid, 22% (95% CI: 19% to 24%) were 250 
 
 
 
 
polymedicated, and 52% (95% CI: 49% to 55%) were any one of the three, i.e., had a 251 
complex health condition (Table 4). Among participants treated for hypertension with 252 
uncontrolled BP-ESC/ESH, 3.1% (95% CI: 1.9% to 4.9%) were frail, 76% (95% CI: 73% to 253 
80%) were multimorbid, 35% (95% CI: 31% to 39%) were polymedicated, and 79% (95% CI: 254 
76% to 82%) were any one of the three, i.e., had a complex health condition. These 255 
proportions were similar if the ACC/AHA threshold was used for defining elevated and 256 
uncontrolled BP. 257 
 258 
Discussion 259 
 260 
Elevated BP is high among older adults and only about half of treated hypertensive older 261 
adults have their BP controlled under the currently applied 2018 ESC/ESH guidelines. 262 
Applying the 2017 ACC/AHA guidelines threshold of 130/80 mmHg for diagnosing 263 
hypertension leads to a large increase in the prevalence of elevated BP and a large decrease in 264 
BP control in our sample. The prevalence of elevated BP was 39% under ESC/ESH 2018 and 265 
63% under ACC/AHA 2017, 24% percentage points higher. The proportion of controlled BP 266 
among individuals treated for hypertension was 56% under ESC/ESH 2018 and 32% under 267 
ACC/AHA 2017, 24% percentage points lower. Finally, about one of two participants with 268 
elevated BP and four out of five participants with uncontrolled BP had a complex health 269 
condition using either threshold. 270 
 271 
The prevalence of elevated BP and BP control vary across time, countries and studies, for the 272 
most part because they depend on how hypertension and elevated BP are defined, on BP 273 
measurement procedures, and on the age distribution of participants. Danon-Hersch et al. 274 
found that, in a subgroup of participants aged 65 to 75 years in a cohort study including 275 
 
 
 
 
residents of the city of Lausanne in Switzerland, the prevalence of hypertension (BP ≥140/90 276 
mmHg or treated for hypertension) was 75% in men and 59% in women and the prevalence of 277 
BP control (<140/90 mmHg) among the treated was 24% in men and 26% in women [23]. In 278 
another study by Brindel et al. including 9090 participants aged 65 years and more from 3 279 
cities in France, the prevalence of elevated BP (BP ≥140/90 mmHg) was 63% and the 280 
prevalence of hypertension (BP ≥140/90 mmHg or treated for hypertension) was 78% [24].  281 
 282 
Several studies have investigated the impact of the 2017 ACC/AHA guidelines on prevalence 283 
and control of elevated BP. Nevertheless, to our knowledge, only few focused on older adults. 284 
For instance, Khera et al. assessed the impact of applying the threshold of 130/80 and 140/90 285 
mmHg on the prevalence of hypertension on the American and the Chinese population aged 286 
45 to 70 years. They found that the prevalence of hypertension increased from 50% to 63% in 287 
the American sample and from 38% to 55% in the Chinese sample [5]. In a more recent study 288 
by Gijón-Conde et al., the prevalence of hypertension increased from 33% to 47% in a 289 
population aged 18 years and over and from 76% to 87% in the subgroup of participants aged 290 
75 years and more [6]. They also found that the prevalence of controlled BP among treated 291 
hypertensive individuals decreased markedly, from 38% to 25%. 292 
  293 
As in all observational research, our study does have limitations. Firstly, data on hypertension 294 
diagnosis and antihypertensive medication use were self-reported. The reliability may be 295 
questionable especially with regard to older participants, who may have difficulty recalling 296 
diagnoses and especially treatments. Secondly, while the study is population-based, the 297 
representativeness of our analytical sample is disputable. With a participation proportion of 298 
48%, there may have been some selection bias. Furthermore, 12% of participants withdrew 299 
from the study and 8% died, which may have introduced some attrition and survivorship bias 300 
 
 
 
 
[25]. Taken together, these factors may have led to a sample that is healthier and more 301 
educated compared to the general population in the same age range. Regardless of which 302 
guideline is considered, the prevalence of elevated BP may have been underestimated and 303 
control rates overestimated [26, 27].  304 
 305 
A third limitation is that BP was measured three times at one visit, what is suitable for 306 
detecting elevated BP at the time of the visit but not for detecting sustained elevated BP. BP 307 
fluctuates with time, according to the time of the day, but also depending on the day, the 308 
month and the season [28, 29]. Similarly, three measurements at one visit are not sufficient 309 
for detecting hypertension in the participants and deciding upon the initiation or 310 
intensification of antihypertensive medication. For diagnosing hypertension, guidelines 311 
recommend having repeated BP readings at several visits, or using home or ambulatory BP 312 
monitoring, to have a better estimate of the true sustained elevated BP, particularly among 313 
older adults [1, 2].  314 
 315 
On the other hand, our study has several strengths. It is based on data from a carefully 316 
conducted study focusing on a population of older age. Loss to follow-up is a major threat to 317 
longitudinal studies but the investigators made an active and sustained effort to collect data on 318 
each participant as long as possible, mitigating attrition. For instance, for participants having 319 
trouble getting to the research center due to physical or cognitive impairments, research 320 
assistants performed home visits following a standardized study protocol. Follow-up was also 321 
maintained as far as possible for individuals entering a nursing home. Another strength of our 322 
study is the accuracy of BP measurements. BP was measured by trained research assistants 323 
following a standardized protocol that was maintained across years and samples. 324 
 325 
 
 
 
 
The substantial increase in the prevalence of elevated BP and decrease in the proportion of 326 
controlled BP if the ACC/AHA threshold was applied has important implications. Bress et al. 327 
estimated that achieving the 2017 ACC/AHA thresholds over 10 years of treatment could 328 
prevent 3 million CVD events in the adult population in the United States, that is 1.4 million 329 
more compared to thresholds <140/90 mmHg. These authors also estimated that achieving the 330 
2017 ACC/AHA thresholds would produce a large number of serious adverse events. Of 331 
notice, these numbers were estimated with the strong assumption of perfect BP control [30]. 332 
In terms of hypertension management, applying the ACC/AHA recommendations would 333 
imply huge increases in efforts from health care providers and patients for hypertension 334 
management to lower BP. It would also require an increase in the capacity and a 335 
strengthening of the accountability of the health system to conduct surveillance and 336 
monitoring, and to respond appropriately to BP levels [31]. Furthermore, because BP control 337 
is currently already poor, one major concern is whether the ACC/AHA threshold is concretely 338 
reachable in clinical practice. 339 
 340 
Opinions diverge on whether the ACC/AHA thresholds should be adopted or not. Wilt et al. 341 
were sceptical that the benefit-harm balance of lowering BP below 130/80 mmHg in the 342 
population falls on the side of benefit [7]. They mentioned that the ACC/AHA 2017 343 
guidelines do not adequately weight the potential benefits against potential harms, costs and 344 
individual patient preferences [7]. Potential risks for patients may include overdiagnosis, 345 
labelling, and adverse effects due to unnecessary medication intake [32]. Bell et al. analyzed 346 
the incremental health benefits, i.e., CVD and mortality reduction, and the incremental harms, 347 
i.e., labeling, financial burden, and treatment burden, of lowering BP thresholds to the 348 
ACC/AHA levels in different patient groups, and they concluded that incremental harms and 349 
benefits were roughly in balance in the elderly population [33]. Conversely,  some others see 350 
 
 
 
 
the expanded definition of hypertension as an important public health opportunity, the 351 
primary aim of which is not to reduce or to control BP, per se, but to maximize CVD risk 352 
reduction in individuals and in the population [34]. In other words, more ambitious targets 353 
would contribute to shifting BP levels downwards in the population.  354 
 355 
Finally, divergences in recommendations result partly from the absence of strong evidence 356 
especially for individuals with complex health conditions [35]. The ESC/ESH 2018 357 
recommends accounting for the patient’s clinical condition, concomitant treatments, and 358 
frailty in the decision on whether to treat hypertension and the ACC/AHA 2017 recommends 359 
an assessment of risks and benefits of the intensity of hypertension treatment in patients with 360 
high comorbidity burden and limited life expectancy (Table 1). According to our results, a 361 
large proportion of older adults are either frail, polymedicated, or multimorbid, stressing the 362 
need for further trials in this population [2, 3, 13]. 363 
 364 
In conclusion, the prevalence of elevated BP under the currently applied ESC/ESH guidelines 365 
is high among older adults, and applying the ACC/AHA hypertension management guidelines 366 
would likely lead to a much larger proportion of older adults treated for elevated BP. Further, 367 
currently only about half of treated hypertensive older adults have their BP controlled, and, if 368 
the ACC/AHA guidelines were applied, BP control would drop even lower. To comply with 369 
the recent American guidelines, considerable effort in hypertension detection and 370 
antihypertensive treatment intensification would be required to lower BP below 130/80 371 
mmHg among older adults. At the same time, it is still debated whether more intensive 372 
treatment is beneficial in older adults, especially considering the high prevalence of complex 373 
health conditions in older adults, for whom the evidence from clinical trials is weak, leaving 374 
health care professionals with unclear recommendations and uncertainty. 375 
376 
 
 
 
 
Conflict of interests 377 
 378 
There is no conflict of interest to disclose. The Lc65+ study has been supported by University 379 
of Lausanne Hospital Centre; University of Lausanne Department of Ambulatory Care and 380 
Community Medicine; Canton de Vaud Department of Public Health; City of Lausanne; 381 
Loterie Romande [research grants 2006-2008 and 2018-2019]; Lausanne University Faculty 382 
of Biology and Medicine [multidisciplinary research grant 2006]; Swiss National Foundation 383 
for Scientific Research [grant 3247B0-120795/1]; and Fondation Médecine Sociale et 384 
Préventive, Lausanne. The sponsors had no role in the design, execution, analysis and 385 
interpretation of data, or writing of the study. 386 
 387 
 388 
Acknowledgments 389 
 390 
Not Applicable. 391 
 392 
Funding 393 
 394 
There was no specific funding for this project.  395 
 
 
 
 
References 396 
 397 
1. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, 398 
et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline 399 
for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: 400 
Executive Summary: A Report of the American College of Cardiology/American Heart 401 
Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-324. 402 
2. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 403 
ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 404 
2018;39(33):3021-104. 405 
3. Anker D, Santos-Eggimann B, Santschi V, Del Giovane C, Wolfson C, Streit S, et al. 406 
Screening and treatment of hypertension in older adults: less is more? Public Health Rev. 407 
2018;39:26. 408 
4. Karmali KN, Lloyd-Jones DM, van der Leeuw J, Goff DC, Jr., Yusuf S, Zanchetti A, et al. 409 
Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood 410 
pressure: A meta-analysis of individual participant data. PLoS Med. 2018;15(3):e1002538. 411 
5. Khera R, Lu Y, Lu J, Saxena A, Nasir K, Jiang L, et al. Impact of 2017 ACC/AHA 412 
guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in 413 
United States and China: nationally representative cross sectional study. BMJ. 414 
2018;362:k2357. 415 
6. Gijon-Conde T, Sanchez-Martinez M, Graciani A, Cruz JJ, Lopez-Garcia E, Ortola R, et al. 416 
Impact of the European and American guidelines on hypertension prevalence, treatment, and 417 
cardiometabolic goals. J Hypertens. 2019;37(7):1393-400. 418 
 
 
 
 
7. Wilt TJ, Kansagara D, Qaseem A, Clinical Guidelines Committee of the American College 419 
of Physicians. Hypertension Limbo: Balancing Benefits, Harms, and Patient Preferences 420 
Before We Lower the Bar on Blood Pressure. Ann Intern Med. 2018;168(5):369-70. 421 
8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. 422 
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of 423 
individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-424 
13. 425 
9. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, 426 
et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in 427 
Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA. 2016;315(24):2673-82. 428 
10. Husten L. Search Results for: SPRINT. 2017 Nov 14 [cited 2019 Jul 15]. In: CardioBrief 429 
[Internet]. Available from: http://www.cardiobrief.org/?s=SPRINT. 430 
11. Richmond R, Law J, Kay-Lambkin F. Higher blood pressure associated with higher 431 
cognition and functionality among centenarians in Australia. Am J Hypertens. 432 
2011;24(3):299-303. 433 
12. Sabayan B, Oleksik AM, Maier AB, van Buchem MA, Poortvliet RK, de Ruijter W, et al. 434 
High blood pressure and resilience to physical and cognitive decline in the oldest old: the 435 
Leiden 85-plus Study. J Am Geriatr Soc. 2012;60(11):2014-9. 436 
13. Benetos A, Petrovic M, Strandberg T. Hypertension Management in Older and Frail Older 437 
Patients. Circ Res. 2019;124(7):1045-60. 438 
14. Santos-Eggimann B, Karmaniola A, Seematter-Bagnoud L, Spagnoli J, Bula C, Cornuz J, 439 
et al. The Lausanne cohort Lc65+: a population-based prospective study of the manifestations, 440 
determinants and outcomes of frailty. BMC Geriatr. 2008;8:20. 441 
 
 
 
 
15. Ville de Lausanne. Contrôle des habitants. [Internet]. Available from 442 
http://www.lausanne.ch/lausanne-officielle/administration/securite-et-economie/controle-des-443 
habitants.html. Accessed 28.06.2019. 444 
16. The Lc65+ cohort. Sampling. [Internet]. Available from 445 
https://lc65plus.iumsp.ch/en/content/sampling. Accessed 08.04.2019. 446 
17. Anker D, Santos-Eggimann B, Zwahlen M, Santschi V, Rodondi N, Wolfson C, et al. 447 
Blood pressure in relation to frailty in older adults: A population-based study. J Clin 448 
Hypertens (Greenwich). 2019. 449 
18. El Assaad MA, Topouchian JA, Darne BM, Asmar RG. Validation of the Omron HEM-450 
907 device for blood pressure measurement. Blood Press Monit. 2002;7(4):237-41. 451 
19. White WB, Anwar YA. Evaluation of the overall efficacy of the Omron office digital 452 
blood pressure HEM-907 monitor in adults. Blood Press Monit. 2001;6(2):107-10. 453 
20. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in 454 
older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56. 455 
21. Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring 456 
multimorbidity: a systematic review of systematic reviews. Eur J Public Health. 457 
2019;29(1):182-9. 458 
22. Benetos A, Rossignol P, Cherubini A, Joly L, Grodzicki T, Rajkumar C, et al. 459 
Polypharmacy in the Aging Patient: Management of Hypertension in Octogenarians. JAMA. 460 
2015;314(2):170-80. 461 
23. Danon-Hersch N, Marques-Vidal P, Bovet P, Chiolero A, Paccaud F, Pecoud A, et al. 462 
Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general 463 
population: the CoLaus study. Eur J Cardiovasc Prev Rehabil. 2009;16(1):66-72. 464 
 
 
 
 
24. Brindel P, Hanon O, Dartigues JF, Ritchie K, Lacombe JM, Ducimetiere P, et al. 465 
Prevalence, awareness, treatment, and control of hypertension in the elderly: the Three City 466 
study. J Hypertens. 2006;24(1):51-8. 467 
25. Gordis L. Epidemiology. 5 ed. Philadelphia, PA: Elsevier Saunders; 2013. 416 p. 468 
26. Brummett BH, Babyak MA, Siegler IC, Shanahan M, Harris KM, Elder GH, et al. 469 
Systolic blood pressure, socioeconomic status, and biobehavioral risk factors in a nationally 470 
representative US young adult sample. Hypertension. 2011;58(2):161-6. 471 
27. Marmot M, Bell R. Fair society, healthy lives. Public Health. 2012;126 Suppl 1:S4-S10. 472 
28. Moore MN, Atkins ER, Salam A, Callisaya ML, Hare JL, Marwick TH, et al. Regression 473 
to the mean of repeated ambulatory blood pressure monitoring in five studies. J Hypertens. 474 
2019;37(1):24-9. 475 
29. Chiolero A, Anker D. Screening interval: a public health blind spot. Lancet Public Health. 476 
2019;4(4):e171-e2. 477 
30. Bress AP, Muntner P, Moran AE. Response by Bress et al to Letters Regarding Article, 478 
"Potential Cardiovascular Disease Events Prevented With Adoption of the 2017 American 479 
College of Cardiology/American Heart Association Blood Pressure Guideline". Circulation. 480 
2019;139(23):e1023-e4. 481 
31. Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to 482 
action and a lifecourse strategy to address the global burden of raised blood pressure on 483 
current and future generations: the Lancet Commission on hypertension. Lancet. 484 
2016;388(10060):2665-712. 485 
32. Moynihan RN, Clark J, Albarqouni L. Media Coverage of the Benefits and Harms of the 486 
2017 Expanded Definition of High Blood Pressure. JAMA Intern Med. 2019;179(2):272-3. 487 
 
 
 
 
33. Bell KJL, Doust J, Glasziou P. Incremental Benefits and Harms of the 2017 American 488 
College of Cardiology/American Heart Association High Blood Pressure Guideline. JAMA 489 
Intern Med. 2018;178(6):755-7. 490 
34. Flack JM, Calhoun D, Schiffrin EL. The New ACC/AHA Hypertension Guidelines for the 491 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Am J 492 
Hypertens. 2018;31(2):133-5. 493 
35. Messerli FH, Bangalore S. The Blood Pressure Landscape: Schism Among Guidelines, 494 
Confusion Among Physicians, and Anxiety Among Patients. J Am Coll Cardiol. 495 
2018;72(11):1313-6. 496 
497 
 
 
 
 
Figure 1. Flow chart with total target population at each sampling period, number of residents 498 
invited, recruited and included in our analytical sample [35]. 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
C1, sample 1, for which recruitment started in 2004; C2, sample 2, for which recruitment 520 
started in 2009; C3, sample 3, for which recruitment started in 2014; N, total number of 521 
participants in the Lc65+; n, number of individuals. 522 
Participants recruited in: 
• C1 (2004), n=1564 
• C2 (2009), n=1489 
• C3 (2014), n=1678  
Participants in the 
Lausanne cohort Lc65+ 
study, N=4731 
Reasons for non-participation in 
most recent data collection: 
• Deceased, n=381 
• Quit the study, n=569 
• Other, n=130 
Reasons for missing data: 
• Only questionnaire 
data, n=394 
• Missing data BP, n=47 
Total population in Lausanne at time of 
recruitment: 
• 2004: birth year 1934-1938, n=4879  
• 2009: birth year 1939-1943, n=4921 
• 2014: birth year 1944-1948, n=5375 
Individuals invited for 
participation: 
• Sample 1 (2004), n=3053  
• Sample 2 (2009), n=3179  
• Sample 3 (2014), n=3655 
Participants with data at 
most recent data 
collection, n=3651 
Participants with 
complete data for BP, 
n=3210 
Reasons for non-participation in 
the study: 
• Non-response, n=3942  
• Refusal, n=1201 
• Errors, n=13 
 
 
 
 
Figure 2. Prevalence and 95% CI of individuals with controlled blood pressure (BP) 523 
according to ESC/ESH 2018 BP thresholds (<140/90 mmHg) compared to  524 
ACC/AHA thresholds (<130/80 mmHg), stratified by sex and age group [1, 2]. yr: years; 525 
ESC/ESH: European Society of Cardiology/European Society of Hypertension; ACC/AHA: 526 
American College of Cardiology and the American Heart Association; BP: blood pressure; 527 
CI, confidence interval. 528 
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Table 1. Blood pressure (BP) thresholds for the definition of hypertension, for the initiation of antihypertensive treatment, and BP target 
during treatment recommended by the European Society of Cardiology/European Society of Hypertension (ESC/ESH ) guidelines 2018 and 
the American College of Cardiology and the American Heart Association (ACC/AHA) guidelines 2017 [1, 2].  
 ESC/ESH 2018  ACC/AHA 2017  
 Definition of HTN 
BP threshold for 
antihypertensive 
treatment initiation 
BP targets Definition of HTN 
BP threshold for 
antihypertensive 
treatment initiation 
BP targets 
All 
adults 
• ≥140/90 • ≥140/90 
 
 
• First objective <140/90 
• Second objective 
<130/80 (not <120/70) 
• ≥130/80 • ≥130/80 in secondary 
prevention 
 
• ≥130/80 in primary 
prevention with a 10-
year ASCVD risk ≥10% 
 
• ≥140/90 in primary 
prevention with a 10-
year ASCVD risk <10% 
• HTN + 10-year ASCVD risk 
≥10%: <130/80 is 
recommended 
• HTN + 10-year ASCVD risk 
<10%: <130/80 is 
reasonable 
 
 
       
Older 
adults 
• ≥140/90 • 80 yr and more: 
≥160/90 
• 65 yr and more: systolic 
BP 130-139 with close 
monitoring of adverse 
effects (not < 130/70) 
 
• The decision to treat 
HTN must take into 
account the patient’s 
clinical condition, 
concomitant treatments, 
and frailty 
• ≥130/80 • Individuals aged >79 yr 
old generally have a 
10-year ASCVD risk 
≥10%, therefore the 
treatment threshold is 
≥130/80 
• 65 yr and more:  
• Noninstitutionalized, 
ambulatory, community-
dwelling patients: <130 
 
• Patient with high burden 
of comorbidities and 
limited life expectancy: 
risk and benefits of 
treatment intensity have to 
be assessed 
BP values are in mmHg. BP: blood pressure; CVD: cardiovascular disease; HTN: hypertension; yr: years; ESC/ESH : European Society of 
Cardiology/European Society of Hypertension; ACC/AHA: American College of Cardiology and the American Heart Association; ASCVD: 
Atherosclerotic Cardiovascular Disease. 
 
 
 
 
 
Table 2. Baseline characteristics of participants (n=3210) 
Characteristics   n (%) 
Sex Women 1888 (59) 
 Men 1322 (41) 
Age [years], mean (SD)  73.3 (4.1) 
Socioeconomic characteristics Living alone 2113 (66) 
 Education  
   Basic compulsory 527 (16)  
   Apprenticeship 1239 (39) 
   High school 805 (25) 
   University 631 (20) 
 Financial difficulties 834 (26) 
 
Missing at least one variable in 
socioeconomic characteristics 80 (2.5) 
BP [mmHg], mean (SD) Systolic BP 135.1 (18.5) 
 Diastolic BP 76.3 (11.0) 
Hypertension Hypertension  1622 (51) 
 Hypertension treatment 1401 (44) 
 
Missing hypertension or antihypertensive 
treatment 6 (0.2) 
Other CVD risk factors Hypercholesterolemia 1138 (35) 
 Diabetes 356 (11) 
 History of CVD 824 (26) 
 Smoking   
   Current smoker 516 (16) 
   Former smoker 1308 (41) 
   Never smoker 1376 (43) 
 
Missing at least one variable in other 
CVD risk factors 28 (0.9) 
BMI category Underweight (BMI < 18.5 kg/m2) 48 (2) 
 Normal (BMI 18.5-24.9 kg/m2) 1139 (35) 
 Overweight (BMI 25-29.9 kg/m2) 1304 (41) 
 Obese (BMI ≥ 30 kg/m2) 709 (22) 
 Missing 10 (0.3) 
Multimorbidity  1740 (48) 
Polypharmacy  751 (21) 
Frailty 114 (3.6) 
Values are counts (%) unless indicated otherwise. n: number of participants; SD: standard 
deviation; BP: blood pressure; CVD: cardiovascular disease; multimorbidity: ≥ self-reported 
chronic diseases; polypharmacy: self-reported use of ≥ 5 medication at least once a week. 
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Table 3. Prevalence and 95% confidence interval (CI) of hypertension (diagnosed with, or treated for), antihypertensive treatment, elevated BP-ESC/ESH 
(≥140/90 mmHg) and elevated BP-ACC/AHA (≥130/80 mmHg), stratified by sex and age [1, 2].  
 Men    Women    Men & Women 
 
67-70 yr 
(n=465) 
71-75 yr 
(n=367) 
76-80 yr 
(n=490) 
All age groups 
(n=1322) 
67-70 yr 
(n=607) 
71-75 yr 
(n=526) 
76-80 yr 
(n=755) 
All age groups 
(n=1888) 
All age groups 
(n=3210) 
Hypertensive  54 (50-59) 
56 
(51-61) 
61 
(57-66) 
57 
(55-60) 
38 
(34-42) 
44 
(39-48) 
 53 
(49-57)  
46 
(43-48) 
51 
(49-52) 
Treated for hypertension 50 (44-55) 
46 
(42-51) 
55 
(50-59) 
50 
(48-53) 
31 
(28-35) 
37 
(33-41) 
47 
(44-51) 
39 
(37-41)  
44 
(42-46) 
Elevated BP-ESC/ESH  
(≥ 140/90 mmHg) 
45 
(41-50) 
45 
(40-50) 
48 
(44-53) 
46 
(44-49) 
31 
(27-35) 
30 
(26-34) 
39 
(35-43) 
34 
(32-36) 
39 
(37-41) 
Elevated BP-ACC/AHA  
(≥ 130/80 mmHg) 
74 
(69-78) 
66 
(61-71) 
69 
(64-73) 
70 
(67-72) 
55 
(51-59) 
54 
(50-59) 
63 
(59-66) 
58 
(56-60) 
63 
(61-64) 
BP: blood pressure; n: number of participants; yr: years; ESC/ESH : European Society of Cardiology/European Society of Hypertension; ACC/AHA: American 
College of Cardiology and the American Heart Association.  
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Table 4. Proportion with 95% confidence interval (CI) of complex health conditions among participants with elevated BP and uncontrolled BP. 
    Complex health condition, % (95% CI) 
 
Total n Frail Multimorbid Polymedicated Frail, multimorbid or polymedicated 
Men      
with elevated BP      
    ≥ 140/90 611 2.6% (1.5-4.2) 47% (43-51) 21% (18-25) 50% (46-54) 
    ≥ 130/80 920 2.3% (1.4-3.5) 48% (45-52) 23% (20-25) 51% (48-55) 
treated for HTN and with 
uncontrolled BP      
    ≥ 140/90 308 3.6% (1.8-6.4) 78% (73-83) 36% (30-42) 81% (76-85) 
    ≥ 130/80 478 3.1 (1.7-5.0) 76% (72-80) 36% (31-40) 79% (75-83) 
Women      
with elevated BP      
    ≥ 140/90 637 2.5% (1.4-4.1) 50% (46-54) 22% (19-25) 55% (51-58) 
    ≥ 130/80 1091 3.4 (2.4-4.7) 47% (44-50) 21% (18-23) 52% (49-55) 
treated for HTN and with 
uncontrolled BP      
    ≥ 140/90 309 2.6% (1.1-5.1) 74% (69-79) 34% (28-39) 77% (72-82) 
    ≥ 130/80 482 3.7% (2.2-5.7) 75% (71-79) 33% (29-37) 78% (75-82) 
All participants      
with elevated BP      
    ≥ 140/90 1248 2.6% (1.8-3.6) 49% (46-51) 22% (19-24) 52% (49-55) 
    ≥ 130/80 2011 2.9% (2.2-3.7) 48% (45-50) 21% (20-23) 52% (49-54) 
treated for HTN and with 
uncontrolled BP      
    ≥ 140/90 617 3.1% (1.9-4.9) 76% (73-80) 35% (31-39) 79% (76-82) 
    ≥ 130/80 960 3.4% (2.3-4.7) 76% (73-78) 34% (31-37) 79% (76-81) 
BP: blood pressure; n: number of participants; HTN: hypertension; CI, confidence interval. 
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Table S1. Baseline characteristics of participants in the original sample (n=3651), the 
analytical sample (n=3210), and in individuals (n=763) with elevated BP under ACC/AHA 
2017 and normal BP ESC/ESH 2018. 
Characteristics  Original 
sample 
Analytical 
sample 
Sample with 
elevated BP under 
ACC/AHA 2017 
Sex Women 59% 59% 60%  
Men 41% 41% 40% 
Age [years], 
mean (SD) 
  73.4 (4.1) 73.3 (4.1) 73.0 (4.1) 
Socioeconomic 
characteristics 
Living alone 66% 66% 69% 
 
Education 
 
  
 
  Basic compulsory 18% 16% 16% 
 
  Apprenticeship 39% 39% 42% 
 
  High school 25% 25% 24% 
 
  University 19% 20% 18%  
Financial difficulties 29% 27% 25% 
 
Missing at least one 
variable in socioeconomic 
characteristics, n (%) 
419 (11%) 80 (2.5%) 18 (2.4%) 
Hypertension Hypertension  46% 45% 46% 
 
Hypertension treatment 44% 44% 45% 
 
Missing hypertension or 
antihypertensive treatment, 
n (%) 
25 (0.7%) 6 (0.2%) 1 (0.1%) 
Other CVD risk 
factors 
Hypercholesterolemia 36% 36% 36% 
 
Diabetes 12% 11% 12%  
History of CVD 26% 26% 23% 
 
Smoking  
 
  
 
  Current smoker 17% 16% 15%  
  Former smoker 40% 41% 40% 
 
  Never smoker 43% 43% 45% 
 
Missing at least one 
variable in other CVD risk 
factors, n (%) 
78 (2.1%) 28 (0.9%) 6 (0.8%) 
BMI category Underweight (BMI < 18.5 
kg/m2) 
1.5% 1.5% 0.7% 
 
Normal (BMI 18.5-24.9 
kg/m2) 
36% 36% 35% 
 
Overweight (BMI 25-29.9 
kg/m2) 
41% 41% 40% 
 
Obese (BMI ≥ 30 kg/m2) 22% 22% 24% 
 
Missing, n (%) 442 (12%) 10 (0.3%) 2 (0.3%) 
Multimorbidity  48% 47% 46% 
Polypharmacy  23% 23% 21% 
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Frailty   3.4% 3.6% 3.4% 
Values are percentages unless indicated otherwise. n: number of participants; SD, standard 
deviation; BP: blood pressure; CVD: cardiovascular disease; multimorbidity:  2 or more self-
reported chronic diseases; polypharmacy: self-reported use of 5 medication or more at least 
once a week.  
 
 
